Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii
Natalia Roson-Calero, Jimmy Lucas, María A Gomis-Font, Roger de Pedro-Jové, Antonio Oliver, Clara Ballesté-Delpierre, Jordi Vila, Marisa Di Pietro, Piyush Baindara · 2024
Read Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii by Natalia Roson-Calero, Jimmy Lucas, María A Gomis-Font, Roger de Pedro-Jové, Antonio Oliver, Clara Ballesté-Delpierre, Jordi Vila, Marisa Di Pietro, Piyush Baindara (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11672505.txt.
Description
Natalia Roson-Calero and co-authors shared a study in twenty twenty-four on a peptide called MV6. MV6 is a synthetic cyclic peptide. It helps a class of drugs called aminoglycosides work better. The target germ is Acinetobacter baumannii. This germ resists many drugs, in part through efflux pumps. Few new cures exist. A booster that brings old drugs back is thus a good path to try.
On its own, MV6 barely killed the germ. With the drugs, it beat a reference pump blocker. The gain was largest with netilmicin. Checkerboard assays showed strong synergy. The team grew spontaneous mutants too. They read the genomes of those mutants. That showed how resistance might emerge. The work presents MV6 as a candidate booster for drugs that fail.
Catalog record
| CREATOR | Natalia Roson-Calero, Jimmy Lucas, María A Gomis-Font, Roger de Pedro-Jové, Antonio Oliver, Clara Ballesté-Delpierre, Jordi Vila, Marisa Di Pietro, Piyush Baindara |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |